MARC details
| 000 -LIDER |
|---|
| fixed length control field |
03446nam a22005415i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-3-319-75184-9 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20210201191438.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180404s2018 gw | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783319751849 |
| -- |
978-3-319-75184-9 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCL |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED062000 |
| Source |
bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCL |
| Source |
thema |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Andrés J. M. Ferreri. |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
1st ed. 2018. |
| 264 #1 - |
|---|
| -- |
Cham : |
| -- |
Springer International Publishing : |
| -- |
Imprint: Springer, |
| -- |
2018. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XIII, 138 p. 14 illus., 13 illus. in color. |
| Other physical details |
online resource. |
| 336 ## - |
|---|
| -- |
text |
| -- |
txt |
| -- |
rdacontent |
| 337 ## - |
|---|
| -- |
computer |
| -- |
c |
| -- |
rdamedia |
| 338 ## - |
|---|
| -- |
online resource |
| -- |
cr |
| -- |
rdacarrier |
| 347 ## - |
|---|
| -- |
text file |
| -- |
PDF |
| -- |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Resistance to Targeted Anti-Cancer Therapeutics, |
| International Standard Serial Number |
2196-5501 ; |
| Volume/sequential designation |
17 |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Acceso multiusuario |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. . |
| 541 ## - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Owner |
UABC ; |
| Method of acquisition |
Temporal ; |
| Date of acquisition |
01/01/2021-12/31/2023. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Cancer research. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Molecular biology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Cancer Research. |
| -- |
https://scigraph.springernature.com/ontologies/product-market-codes/B11001 |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Término temático o nombre geográfico como elemento de entrada |
Molecular Medicine. |
| -- |
https://scigraph.springernature.com/ontologies/product-market-codes/B1700X |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ferreri, Andrés J. M. |
| Relator term |
editor. |
| Relator code |
edt |
| -- |
http://id.loc.gov/vocabulary/relators/edt |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer Nature eBook |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783319751832 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783319751856 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783030091651 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Resistance to Targeted Anti-Cancer Therapeutics, |
| -- |
2196-5501 ; |
| Volume number/sequential designation |
17 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Public note |
Libro electrónico |
| Uniform Resource Identifier |
http://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-75184-9 |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
| 912 ## - |
|---|
| -- |
ZDB-2-SXB |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Libro Electrónico |
